111 Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

111 Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,767	Closed	-$179K	–	500
2025 Q1	$179K	Buy	+10,767	New	+$196K	0.03%	419

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

111 Capital's ACAD Position: Q2 2025 in Review

111 Capital sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 10,767 shares — an estimated $179K sold.

111 Capital first reported a position in ACAD in Q1 2025 and held it in 1 quarter. The position peaked at $179K in Q1 2025. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

111 Capital reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
111 Capital sold 10,767 Acadia Pharmaceuticals shares in Q2 2025, an estimated $179K.
111 Capital first reported a position in Acadia Pharmaceuticals in Q1 2025 and held it in 1 quarter.
111 Capital's Acadia Pharmaceuticals position peaked at $179K in Q1 2025.
311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on 111 Capital's 13F filing for Q2 2025, filed 21 Jul 2025.